WuXi AppTec Co., Ltd. Class H (HK:2359)
:2359
Earnings Data
Report Date
Apr 28, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.39Last Year’s EPS
1.37Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call conveyed a strong financial and operational performance for 2025 with record revenue, expanding margins, robust cash flow and a large, growing backlog. Rapid capacity expansion (especially TIDES) and strong U.S. demand underpin an ambitious 2026 guidance and generous shareholder returns. Key near-term risks noted include regional timing-related revenue variability (Europe & China), margin pressure in Testing and Biology from pricing dynamics, rising inventory/working capital needs, FX and raw-material/geopolitical exposure, and concentration risk around peptides/GLP-1 and new modalities. On balance, the positive operational and financial momentum, clear guidance and capacity-backed backlog materially outweigh the outlined challenges.Company Guidance
Record Revenue and Continuing Operations Growth
Total revenue reached RMB 45.46 billion in 2025; revenue from continuing operations grew 21.4% YoY to RMB 43.42 billion, beating full-year guidance.
Strong Profitability Expansion
Adjusted non-IFRS net profit rose 41.3% YoY to RMB 14.96 billion; adjusted non-IFRS net profit margin improved by 5.9 percentage points to 32.9%.
Improved Gross Profit and Margins
Adjusted non-IFRS gross profit reached RMB 21.89 billion and adjusted gross profit margin expanded 6.6 percentage points YoY to 48.2%.
Significant Backlog and Visibility
Backlog for continuing operations reached RMB 58 billion, up 28.8% YoY, providing strong near-term revenue visibility (management notes ~70% of backlog expected to convert in 2026).
TIDES / New Modalities Rapid Growth
TIDES revenue nearly doubled, up 96% YoY to RMB 11.37 billion; TIDES backlog grew 20.2% YoY, D&M customers increased 25% YoY and number of molecules increased 45% YoY.
WuXi Chemistry Outperformance
WuXi Chemistry revenue grew 25.5% YoY to RMB 36.47 billion; adjusted non-IFRS gross profit margin for chemistry improved 5.9 percentage points to 52.3%.
Cash Flow, Investment Gains and EPS
Adjusted operating cash flow reached a record RMB 16.67 billion, up 39.1% YoY; pretax investment gains exceeded RMB 8 billion; diluted EPS more than doubled to ~RMB 6.63.
Capacity Buildout and Regulatory Success
Small-molecule API reactor volume exceeded 4,000 m3; solid-phase peptide synthesizer capacity >100,000 liters; multiple sites passed FDA/OECD/NMPA/PMDA inspections with no single observation.
Strong U.S. Revenue Growth and Geographic Diversification
Revenue from the U.S. market grew 34.3% YoY; Japan/Korea grew 4.1% YoY; diversified global footprint cited as underpinning stability and resilience.
Ambitious 2026 Guidance and Shareholder Returns
2026 revenue guidance RMB 51.3–53.0 billion (continuing ops growth 18–22% YoY); CapEx guidance RMB 6.5–7.5 billion; adjusted free cash flow expected RMB 10.5–11.5 billion; proposed record cash dividend distribution plan totaling RMB 5.7 billion and continued 30% payout ratio.
Sustainability and Quality Credentials
Achieved MSCI AAA, CDP Climate Change A, CDP Water Security A, EcoVadis Gold, included in S&P Global Sustainability Yearbook for 4th consecutive year; SBTi-validated near-term GHG targets; 741 quality audits and 60 information security audits completed with no critical findings.
HK:2359 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HK:2359 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 23, 2026 | HK$107.00 | HK$102.70 | -4.02% |
Jul 28, 2025 | HK$98.12 | HK$100.06 | +1.98% |
Apr 28, 2025 | HK$55.84 | HK$56.72 | +1.58% |
Mar 17, 2025 | HK$62.86 | HK$63.78 | +1.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does WuXi AppTec Co., Ltd. Class H (HK:2359) report earnings?
WuXi AppTec Co., Ltd. Class H (HK:2359) is schdueled to report earning on Apr 28, 2026, Before Open (Confirmed).
What is WuXi AppTec Co., Ltd. Class H (HK:2359) earnings time?
WuXi AppTec Co., Ltd. Class H (HK:2359) earnings time is at Apr 28, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of WuXi AppTec Co., Ltd. Class H stock?
The P/E ratio of WuXi AppTec Co., Ltd. Class H is N/A.
What is HK:2359 EPS forecast?
HK:2359 EPS forecast for the fiscal quarter 2026 (Q1) is 1.39.